



## Revance to Participate in the 38th Annual J.P. Morgan Healthcare Conference

January 9, 2020

NEWARK, Calif.--(BUSINESS WIRE)--Jan. 9, 2020-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulator products for aesthetic and therapeutic indications, today announced that the company will participate in the 38th Annual J.P. Morgan Healthcare Conference, in San Francisco, CA.

President and Chief Executive Officer Mark Foley is scheduled to present on Thursday, January 16 at 11:30 a.m. PT.

Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at [www.revance.com](http://www.revance.com). The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.

### About Revance Therapeutics, Inc.

Revance Therapeutics is a Silicon Valley-based biotechnology company, pioneering new innovations in neuromodulators for aesthetic and therapeutic indications. Revance's lead product candidate, DaxibotulinumtoxinA for Injection (DAXI), combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. Revance has successfully completed a Phase 3 program for DAXI in glabellar (frown) lines and is pursuing U.S. regulatory approval in 2020. Revance is also evaluating DAXI in the full upper face, including glabellar lines, forehead lines and crow's feet, as well as in three therapeutic indications - cervical dystonia, adult upper limb spasticity and plantar fasciitis, with plans to study migraine. Beyond DAXI, Revance has begun development of a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace. Revance is dedicated to making a difference by transforming patient experiences. For more information or to join our team visit us at [www.revance.com](http://www.revance.com).

"Revance Therapeutics" and the Revance logo are registered trademarks of Revance Therapeutics, Inc. BOTOX® is a registered trademark of Allergan, Inc.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20200109005203/en/>

Source: Revance Therapeutics, Inc.

### Investors

Revance Therapeutics, Inc.:  
Jeanie Herbert, 714-325-3584  
[jherbert@revance.com](mailto:jherbert@revance.com)

or

Gilmartin Group, LLC.:  
Laurence Watts, 619-916-7620  
[laurence@gilmartinir.com](mailto:laurence@gilmartinir.com)

### Media

Revance Therapeutics, Inc.:  
Sara Fahy, 949-887-4476  
[sfahy@revance.com](mailto:sfahy@revance.com)

or

General Media:

Y&R:

Jenifer Slaw, 347-971-0906  
[jenifer.slaw@YR.com](mailto:jenifer.slaw@YR.com)

or

Trade Media:

Nadine Tosk, 504-453-8344  
[nadinepr@gmail.com](mailto:nadinepr@gmail.com)